Philogen targets Angiogenesis for cancer and Autoimmune Therapies

29/07/2016 - 2 minutes

Barcelona was pleasant but once again it’s time to go away! We won’t go far… we’re just crossing the Balearic sea to the shores of Italy and visit Sovicille, a suburban town not far from Sienna, where Swiss-Italian company Philogen, our Biotech of the Week, is based!

philogen logo

City: Sovicille (Italy)

Founded: 1996

Employees: 70

Financial Data: N/A

CEO: Duccio Neri

duccio_neri_ceo_philogen

Mission: Philogen focuses on health disorders related to angiogenesis, the formation of new blood vessels. Besides its normal role, angiogenesis is related to many severe pathologies, including cancer, rheumatoid arthritis and age-related macular degeneration.

As part of its discovery program, Philogen has developed products that target angiogenesis in vivo. It was the first in the world to demonstrate that human monoclonal antibodies can be effective at targeting the neo-vasculature of tumors.

Its work has yielded 5 candidates currently in clinical development.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member